Anne C Bay-Jensen1, Christian S Thudium1, Ali Mobasheri2,3. 1. Rheumatology, Biomarkers and Research, Nordic Bioscience A/S, Herlev, Denmark. 2. Department of Veterinary Pre-Clinical Sciences, School of Veterinary Medicine, Faculty of Health and Medical Sciences, University of Surrey, Guildford. 3. Arthritis Research UK Centre for Sport, Exercise and Osteoarthritis, Queen's Medical Centre, Nottingham, United Kingdom.
Abstract
PURPOSE OF REVIEW: There is an increasing demand for noninvasive and descriptive biochemical markers (biomarkers) in osteoarthritis; for enabling early drug development (including translational research), evaluating clinical trial at an early stage and for subtyping. Purpose of the review is to review and comment on current availability of such biomarkers. RECENT FINDINGS: Many different biomarkers have been tested in the last 18 months. The main focus has been on testing whether the biomarkers, whether is reflect joint tissue turnover or inflammatory status, can differentiate osteoarthritis patients from healthy controls or whether the biomarkers are associated with progression. Less than a handful of studies, investigate the role of the biomarkers as response markers. Thus, there is still a great need for developing biomarkers that reflect disease activity and thereby can be used for treatment response or patient phenotyping. SUMMARY: Osteoarthritis is the most common form of joint disease. This presents the osteoarthritis research community and pharmaceutical companies developing disease-modifying osteoarthritis drugs (DMOADs) with great opportunities. There are different osteoarthritis subtypes, which complicates the traditional approaches for developing new treatments. If we can identify new markers that can distinguish different subtypes, this can greatly facilitate drug development from early discovery to late clinical development.
PURPOSE OF REVIEW: There is an increasing demand for noninvasive and descriptive biochemical markers (biomarkers) in osteoarthritis; for enabling early drug development (including translational research), evaluating clinical trial at an early stage and for subtyping. Purpose of the review is to review and comment on current availability of such biomarkers. RECENT FINDINGS: Many different biomarkers have been tested in the last 18 months. The main focus has been on testing whether the biomarkers, whether is reflect joint tissue turnover or inflammatory status, can differentiate osteoarthritispatients from healthy controls or whether the biomarkers are associated with progression. Less than a handful of studies, investigate the role of the biomarkers as response markers. Thus, there is still a great need for developing biomarkers that reflect disease activity and thereby can be used for treatment response or patient phenotyping. SUMMARY:Osteoarthritis is the most common form of joint disease. This presents the osteoarthritis research community and pharmaceutical companies developing disease-modifying osteoarthritis drugs (DMOADs) with great opportunities. There are different osteoarthritis subtypes, which complicates the traditional approaches for developing new treatments. If we can identify new markers that can distinguish different subtypes, this can greatly facilitate drug development from early discovery to late clinical development.
Authors: Jana Riegger; Martin Rehm; Gisela Büchele; Hermann Brenner; Klaus-Peter Günther; Dietrich Rothenbacher; Rolf E Brenner Journal: J Clin Med Date: 2020-01-18 Impact factor: 4.241
Authors: Eiva Bernotiene; Edvardas Bagdonas; Gailute Kirdaite; Paulius Bernotas; Ursule Kalvaityte; Ilona Uzieliene; Christian S Thudium; Heidi Hannula; Gabriela S Lorite; Mona Dvir-Ginzberg; Ali Guermazi; Ali Mobasheri Journal: Front Med (Lausanne) Date: 2020-10-21
Authors: Christian S Thudium; Signe Holm Nielsen; Samra Sardar; Ali Mobasheri; Willem Evert van Spil; Rik Lories; Kim Henriksen; Anne-Christine Bay-Jensen; Morten A Karsdal Journal: BMC Musculoskelet Disord Date: 2020-11-28 Impact factor: 2.362
Authors: Unnur Styrkarsdottir; Sigrun H Lund; Saedis Saevarsdottir; Magnus I Magnusson; Kristbjorg Gunnarsdottir; Gudmundur L Norddahl; Michael L Frigge; Erna V Ivarsdottir; Gyda Bjornsdottir; Hilma Holm; Gudmundur Thorgeirsson; Thorunn Rafnar; Ingileif Jonsdottir; Thorvaldur Ingvarsson; Helgi Jonsson; Patrick Sulem; Unnur Thorsteinsdottir; Daniel Gudbjartsson; Kari Stefansson Journal: Arthritis Rheumatol Date: 2021-09-28 Impact factor: 10.995